Three different pharmacological efficacy in a single molecule- phenyramidol

Abstract

Purpose: Phenyramidol was first described pharmacologically in 1959 and is used in the treatment of painful musculoskeletal diseases. In this review, a collective evaluation of in silico, in vitro, in vivo, and clinical studies of Phenyramidol, whose analgesic and myorelaxant efficacy was initially defined, was performed. Our aim was to elucidate the clinical effects, safety, and tolerability profile of Phenyramidol. Method: Literature was retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., phenyramidol, spasm, pain, musculoskeletal disorders), without any limitations in terms of the publication date and language. Papers that assessed the therapeutic efficacy and tolerability of phenyramidol were selected for inclusion according to their relevance for the topic, as judged by the authors. Results: In studies, it has been reported that Phenyramidol exhibits an effective and safe analgesic, myorelaxant and anti-inflammatory activity with equivalent analgesic potency to Codeine and Meperidine. It has been shown that with the use of oral or intramuscular Phenyramidol is an effective and safe treatment option that provides up to 94% improvement in painful musculoskeletal disorders and is tolerable in 96.8% of patients. No addictive effects or serious adverse effects on the cardiovascular system have been observed due to oral, parenteral, or concomitant oral and parenteral use of Phenyramidol. It has been reported in studies that oral phenyramidol does not cause any toxicity, does not have an addictive effect, and does not have any significant side effects on the gastrointestinal system even at daily dosages of up to 3200 mg. No serious side effects or mutagenic effects were observed in patients with the use of phenyramidol, and the incidence of side effects was reported to be similar to that of placebo. It has been observed that phenyramidol has strong anti-inflammatory efficacy in silico, in vitro, and in vivo studies, and in addition to having statistically significant higher analgesic efficacy than thiocolchicoside and acetylsalicylic acid, phenyramidol provides anti-inflammatory efficacy equivalent to Ibuprofen and Dexamethasone through balanced cyclooxygenase enzyme inhibition. Conclusion: Phenyramidol, which contains three pharmacological efficacies that are statistically significant potent analgesic, myorelaxant and anti-inflammatory in studies, is an effective and safe treatment option that provides up to 94% improvement in painful musculoskeletal disorders and is tolerable in 96.8% of patients. Phenyramidol, with its analgesic, myorelaxant and anti-inflammatory effects, is a treatment option that can be used as the first choice in the symptomatic treatment of painful musculoskeletal diseases.